182133-35-3 Usage
Description
6-Methoxybenzo[b]thiophene-2-boronic acid is an organic boronic acid compound characterized by the presence of a methoxy group at the 6-position and a boronic acid group at the 2-position on a benzo[b]thiophene ring. This unique structure endows it with versatile reactivity and potential applications in various chemical and pharmaceutical processes.
Uses
Used in Pharmaceutical Industry:
6-Methoxybenzo[b]thiophene-2-boronic acid is used as a key reactant in the synthetic preparation of diaminobenzo[b]thiophenes, which are important active site directed thrombin inhibitors and anticoagulants. These compounds play a crucial role in the development of novel antithrombotic drugs, offering potential therapeutic benefits for the treatment and prevention of blood clot-related disorders.
In the synthesis of diaminobenzo[b]thiophenes, 6-Methoxybenzo[b]thiophene-2-boronic acid serves as a versatile building block, allowing for the introduction of various functional groups and structural modifications. This enables the fine-tuning of the physicochemical properties and biological activities of the resulting thrombin inhibitors, leading to the discovery of more potent and selective antithrombotic agents.
Furthermore, the boronic acid moiety in 6-Methoxybenzo[b]thiophene-2-boronic acid can participate in various coupling reactions, such as Suzuki-Miyaura cross-coupling, providing a convenient and efficient method for the synthesis of diverse diaminobenzo[b]thiophene derivatives with tailored pharmacological profiles.
Overall, 6-Methoxybenzo[b]thiophene-2-boronic acid is a valuable intermediate in the pharmaceutical industry, contributing to the advancement of thrombin inhibitors and anticoagulant drug development. Its unique structural features and synthetic utility make it an attractive candidate for further research and application in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 182133-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,2,1,3 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 182133-35:
(8*1)+(7*8)+(6*2)+(5*1)+(4*3)+(3*3)+(2*3)+(1*5)=113
113 % 10 = 3
So 182133-35-3 is a valid CAS Registry Number.
182133-35-3Relevant articles and documents
2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT
-
Page/Page column 18, (2010/11/03)
2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.
Thrombin inhibitors
-
, (2008/06/13)
This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.
Antithrombotic agents
-
Page column 48, (2010/01/31)
This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
